中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共4条，第1-4条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
A pH-Responsive Yolk-Like Nanoplatform for Tumor Targeted Dual-Mode Magnetic Resonance Imaging and Chemotherapy 期刊论文
ACS NANO, 2017, 卷号: 11, 期号: 7, 页码: 7049-7059
作者:  Sun, Xiao;  Du, Ruohong;  Zhang, Li;  Zhang, Guilong;  Zheng, Xiaojia;  Qian, Junchao;  Tian, Xiaohe;  Zhou, Jiewen;  He, Jiacai;  Wang, Yuanyin;  Wu, Yiqun;  Zhong, Kai;  Cai, Dongqing;  Zou, Duohong;  Wu, Zhengyan
浏览  |  Adobe PDF(2865Kb)  |  收藏  |  浏览/下载：140/39  |  提交时间：2018/08/16
Yolk-like Fe3o4@gd2o3  Targeted  Dual-mode Mr Imaging Drug Delivery System  Cisplatin  Ph Responsive  Cancer Chemotherapy  
Biodegradable Core-shell Dual-Metal-Organic-Frameworks Nanotheranostic Agent for Multiple Imaging Guided Combination Cancer Therapy 期刊论文
THERANOSTICS, 2017, 卷号: 7, 期号: 18, 页码: 4605-4617
作者:  Wang, Dongdong;  Zhou, Jiajia;  Shi, Ruohong;  Wu, Huihui;  Chen, Ruhui;  Duan, Beichen;  Xia, Guoliang;  Xu, Pengping;  Wang, Hui;  Zhou, Shu;  Wang, Chengming;  Wang, Haibao;  Guo, Zhen;  Chen, Qianwang
浏览  |  Adobe PDF(4494Kb)  |  收藏  |  浏览/下载：91/38  |  提交时间：2019/06/17
MOFs  photothermal  chemotherapy  pH-responsive  NIR-responsive  
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2017, 卷号: 29
-
收藏  |  浏览/下载：32/0  |  提交时间：2020/10/26
EGFR MUTATIONS  GEFITINIB TREATMENT  1ST-LINE TREATMENT  OPEN-LABEL  RARE  MULTICENTER  ERLOTINIB  GENE  CHEMOTHERAPY  EFFICACY  Non-small cell lung cancer  EGFR  uncommon mutation  target therapy  
Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice 期刊论文
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2017, 卷号: 18
-
收藏  |  浏览/下载：27/0  |  提交时间：2020/10/26
RANDOMIZED PHASE-III  NEOADJUVANT CHEMOTHERAPY  ENCAPSULATED DOXORUBICIN  1ST-LINE CHEMOTHERAPY  PROGNOSTIC MARKER  PLUS DOCETAXEL  COMBINATION  CYCLOPHOSPHAMIDE  TRASTUZUMAB  PACLITAXEL  Liposomal doxorubicin  Breast cancer  Adjuvant chemotherapy  Therapeutic effect  Toxic and side effects